The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer

Selcukbiricik F., ERDAMAR ÇETİN A. S., Ozkurt C. U., Mandel N. M., DEMİRELLİ F. H., Ozguroglu M., ...Daha Fazla

JOURNAL OF BUON, cilt.18, sa.1, ss.116-123, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 1
  • Basım Tarihi: 2013
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.116-123
  • Anahtar Kelimeler: bevacizumab, biomarker, B-RAF, chemotherapy, K-RAS, metastatic colon cancer, 1ST-LINE TREATMENT, TARGETED THERAPY, BRAF MUTATION, PHASE-III, BEVACIZUMAB, EFFICACY, KRAS, IMPACT, TRIAL
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Purpose: Unlike cetuximab, there is a paucity of biomarkers for bevacizumab as predictors of outcome in metastatic colorectal cancer (mCRC) patients. Obviously exploring the worth of some potential markers in this setting is warranted. The purpose of this study was to investigate the predictive value of the presence of K-RAS and B-RAF mutations on the outcome of patients with mCRC treated with FOLFIRI and bevacizumab combination therapy.